[go: up one dir, main page]

MX2018007669A - Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert. - Google Patents

Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert.

Info

Publication number
MX2018007669A
MX2018007669A MX2018007669A MX2018007669A MX2018007669A MX 2018007669 A MX2018007669 A MX 2018007669A MX 2018007669 A MX2018007669 A MX 2018007669A MX 2018007669 A MX2018007669 A MX 2018007669A MX 2018007669 A MX2018007669 A MX 2018007669A
Authority
MX
Mexico
Prior art keywords
ert
treatment
fabry disease
naã
experienced patients
Prior art date
Application number
MX2018007669A
Other languages
English (en)
Other versions
MX395523B (es
Inventor
Castelli Jeff
Original Assignee
Amicus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/213,920 external-priority patent/US9999618B2/en
Application filed by Amicus Therapeutics Inc filed Critical Amicus Therapeutics Inc
Publication of MX2018007669A publication Critical patent/MX2018007669A/es
Publication of MX395523B publication Critical patent/MX395523B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)

Abstract

Se proveen regímenes de dosificación para el tratamiento de la enfermedad de Fabry en un paciente. Algunos métodos se relacionan con el tratamiento de pacientes con Fabry no tratados previamente o tratados con ERT. Algunos métodos comprenden administrar al paciente aproximadamente 123 mg de equivalentes de base libre de migalastat para mejorar la masa ventricular izquierda y/o para mejorar la globotriaosilceramida en podocitos.
MX2018007669A 2016-07-19 2017-07-19 Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert. MX395523B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15/213,920 US9999618B2 (en) 2007-04-26 2016-07-19 Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
PCT/US2017/042872 WO2018017721A1 (en) 2016-07-19 2017-07-19 Treatment of fabry disease in ert-naïve and ert-experienced patients

Publications (2)

Publication Number Publication Date
MX2018007669A true MX2018007669A (es) 2018-09-12
MX395523B MX395523B (es) 2025-03-25

Family

ID=59416847

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018007669A MX395523B (es) 2016-07-19 2017-07-19 Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert.
MX2022011334A MX2022011334A (es) 2016-07-19 2018-06-20 Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022011334A MX2022011334A (es) 2016-07-19 2018-06-20 Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert.

Country Status (15)

Country Link
US (2) US12070453B2 (es)
EP (5) EP3487502A1 (es)
JP (4) JP6752270B2 (es)
KR (3) KR20190030729A (es)
CN (1) CN109661230A (es)
AR (1) AR109103A1 (es)
AU (3) AU2017298376A1 (es)
CA (1) CA3031249A1 (es)
CL (1) CL2018001677A1 (es)
CO (1) CO2018006358A2 (es)
IL (2) IL313907A (es)
MX (2) MX395523B (es)
NZ (1) NZ790449A (es)
TW (2) TW202408513A (es)
WO (1) WO2018017721A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009537149A (ja) 2006-05-16 2009-10-29 アミークス セラピューティックス インコーポレイテッド ファブリー病に対する治療の選択を診断し、評価するためのアッセイ
PL3470077T3 (pl) 2008-02-12 2021-04-06 Amicus Therapeutics, Inc. Sposób przewidywania odpowiedzi na leczenie chorób chaperonami farmakologicznymi
EP3487502A1 (en) * 2016-07-19 2019-05-29 Amicus Therapeutics, Inc. Treatment of fabry disease in ert-naïve and ert-experienced patients
US12020820B1 (en) * 2017-03-03 2024-06-25 Cerner Innovation, Inc. Predicting sphingolipidoses (fabry's disease) and decision support
HUE065615T2 (hu) 2017-05-30 2024-06-28 Amicus Therapeutics Inc Migalasztát, vesekárosodással szövõdött Fabry-kórban szenvedõ betegeg kezelésére
CA3224546A1 (en) 2017-05-30 2018-12-06 Jeff Castelli Use of migalastat in the treatment of fabry patients having renal impairment
EP3749307B1 (en) * 2018-02-06 2025-12-10 Amicus Therapeutics, Inc. Use of migalastat for treating fabry disease in pregnant patients
RS65103B1 (sr) * 2018-02-06 2024-02-29 Amicus Therapeutics Inc Lečenje bolesnika sa klasičnom fabrijevom bolešću migalastatom
ES2993833T3 (en) * 2018-08-20 2025-01-10 Amicus Therapeutics Inc Migalastat for use in methods of treating fabry disease in patients having a mutation in the gla gene
TW202042812A (zh) * 2019-01-22 2020-12-01 美商阿米庫斯醫療股份有限公司 減少法布瑞氏症患者中之腦血管事件之方法
BR112021024886A2 (pt) * 2019-06-11 2022-01-25 Amicus Therapeutics Inc Métodos de tratar a doença de fabry em pacientes com insuficiência renal
JP2021024864A (ja) 2019-08-07 2021-02-22 アミカス セラピューティックス インコーポレイテッド Ｇｌａ遺伝子に突然変異を有する患者のファブリー病を治療する方法
AU2021218578A1 (en) * 2020-02-10 2022-08-25 Amicus Therapeutics, Inc. Methods of treating Fabry disease
US11623916B2 (en) 2020-12-16 2023-04-11 Amicus Therapeutics, Inc. Highly purified batches of pharmaceutical grade migalastat and methods of producing the same
KR102471225B1 (ko) 2021-11-18 2022-11-28 박기용 어플리케이션을 통한 소비자 및 농장 연결 시스템

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0463109A4 (en) 1989-03-24 1992-11-19 Research Corporation Technologies, Inc. Recombinant alpha-galactosidase, a therapy for fabry disease
CA2086413A1 (en) 1990-06-29 1991-12-30 Yohji Ezure Piperidine derivatives
EP0959877A4 (en) 1996-04-10 2000-08-23 Univ California CORRECTION OF GENETIC ERRORS USING CHEMICAL COMPANIES
US6270954B1 (en) 1996-04-10 2001-08-07 The Regents Of The University Of California Correction of genetic defects using chemical chaperones
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
DK1589993T3 (en) 2003-01-31 2015-03-09 Sinai School Medicine COMBINATION THERAPY FOR TREATMENT OF PROTEIN FAILURE DISORDERS
US7446098B2 (en) 2003-02-18 2008-11-04 Mount Sinai School Of Medicine Of New York University Combination therapy for treating protein deficiencies
EP1682134A4 (en) 2003-11-12 2008-10-15 Amicus Therapeutics Inc GLUCOIMIDAZOLE AND POLYHYDROXYCYCLOHEXENYL-AMINE DERIVATIVES FOR THE TREATMENT OF GAUCHER DISEASE
CA2612538C (en) 2005-05-17 2015-06-30 Amicus Therapeutics, Inc. A method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives
CN104771402A (zh) 2005-06-08 2015-07-15 阿米库斯治疗学公司 溶酶体酶编码基因突变相关的cns紊乱的治疗
US7955262B2 (en) 2005-07-26 2011-06-07 Syneron Medical Ltd. Method and apparatus for treatment of skin using RF and ultrasound energies
CN101267779A (zh) 2005-07-27 2008-09-17 福罗里达大学研究基金会有限公司 使用热休克治疗眼睛疾病
AU2015230773B2 (en) * 2006-05-16 2017-09-28 Amicus Therapeutics Inc. Assays for diagnosing and evaluating treatment options for fabry disease
JP2009537149A (ja) * 2006-05-16 2009-10-29 アミークス セラピューティックス インコーポレイテッド ファブリー病に対する治療の選択を診断し、評価するためのアッセイ
ATE500226T1 (de) 2006-09-22 2011-03-15 Krka Tovarna Zdravil D D Novo Mesto Aripiprazolhemifumarat und verfahren zu dessen herstellung
US20100113517A1 (en) 2007-03-30 2010-05-06 Amicus Therapeutics, Inc. Method for the treatment of fabry disease using pharmacological chaperones
PL3470077T3 (pl) 2008-02-12 2021-04-06 Amicus Therapeutics, Inc. Sposób przewidywania odpowiedzi na leczenie chorób chaperonami farmakologicznymi
SG193379A1 (en) * 2011-03-11 2013-10-30 Amicus Therapeutics Inc Dosing regimens for the treatment of fabry disease
JP2013255488A (ja) 2012-05-18 2013-12-26 Saitama Medical Univ 拡張期心不全非ヒトモデル動物及びその製造方法、並びに、拡張期心不全予防乃至症状改善活性を有する物質のスクリーニング方法
EP3487502A1 (en) * 2016-07-19 2019-05-29 Amicus Therapeutics, Inc. Treatment of fabry disease in ert-naïve and ert-experienced patients

Also Published As

Publication number Publication date
AU2017298376A1 (en) 2019-03-07
AR109103A1 (es) 2018-10-31
EP4378524A2 (en) 2024-06-05
JP2022033749A (ja) 2022-03-02
JP2018526368A (ja) 2018-09-13
JP6752270B2 (ja) 2020-09-09
KR20230061563A (ko) 2023-05-08
EP4389213A3 (en) 2024-08-21
KR20190030729A (ko) 2019-03-22
MX395523B (es) 2025-03-25
CA3031249A1 (en) 2018-01-25
AU2023206175A1 (en) 2023-08-10
EP4324521A3 (en) 2024-04-24
IL264301A (en) 2019-02-28
EP4378524A3 (en) 2024-08-14
US20230321065A1 (en) 2023-10-12
AU2023206175B2 (en) 2025-05-22
US12070453B2 (en) 2024-08-27
MX2022011334A (es) 2022-10-07
TWI875676B (zh) 2025-03-11
EP4324521A2 (en) 2024-02-21
JP2024026079A (ja) 2024-02-28
WO2018017721A1 (en) 2018-01-25
CO2018006358A2 (es) 2018-11-30
NZ750752A (en) 2025-07-25
CN109661230A (zh) 2019-04-19
TW202408513A (zh) 2024-03-01
CL2018001677A1 (es) 2019-02-01
AU2025217396A1 (en) 2025-09-04
JP2019178140A (ja) 2019-10-17
NZ790449A (en) 2025-08-29
EP4389213A2 (en) 2024-06-26
TW201806597A (zh) 2018-03-01
EP4356911A1 (en) 2024-04-24
KR20240017126A (ko) 2024-02-06
US20190183869A1 (en) 2019-06-20
IL313907A (en) 2024-08-01
EP3487502A1 (en) 2019-05-29

Similar Documents

Publication Publication Date Title
CO2018006358A2 (es) Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert
MX2024010140A (es) Nuevos metodos.
CY1124135T1 (el) Δοσολογικα σχηματα για την αγωγη της νοσου ρομρε
MX2023012450A (es) Esketamina para el tratamiento de la depresion.
MX2023005628A (es) Metodos para aumentar y/o estabilizar la funcion cardiaca en pacientes con enfermedad de fabry.
MX2022004137A (es) Metodos de tratamiento de pacientes con enfermedad de fabry que tienen insuficiencia renal.
EA202090242A1 (ru) Лечение болезни фабри у фзт-наивных и фзт-леченных пациентов
AR089862A1 (es) USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA
MX383665B (es) Composiciones de donepezilo y métodos para tratar la enfermedad de alzheimer.
NI201700024A (es) Tratamientos médicos a base de anamorelina
CL2021003280A1 (es) Métodos para tratar la enfermedad de fabry en pacientes que tienen insuficiencia renal
AR114392A1 (es) Tratamiento de pacientes con enfermedad de fabry clásica
AR111374A1 (es) Uso de lik066 en pacientes con insuficiencia cardíaca
EA202191165A1 (ru) Элацестрант в комбинации с абемациклибом у женщин с раком молочной железы
MX379253B (es) Formulaciones de oximetazolina estabilizadas y sus usos.
PH12015502655A1 (en) Method
AR117861A1 (es) Métodos de reducción de eventos cerebrovasculares en pacientes con enfermedad de fabry
EA202090416A1 (ru) Способы лечения симптомов гастропареза с использованием велусетрага
MX385725B (es) Composición farmacéutica que comprende sumatriptán para tratamiento de migraña.
EA202190247A1 (ru) ПРИМЕНЕНИЕ рГЦ СТИМУЛЯТОРОВ ДЛЯ ЛЕЧЕНИЯ МИТОХОНДРИАЛЬНЫХ ЗАБОЛЕВАНИЙ
UA111312C2 (uk) Спосіб лікування гострого коронарного синдрому без елевації сегмента st у пацієнтів з ішемічною хворобою серця та метаболічним синдромом, що перенесли перкутанну транслюмінарну коронарну ангіопластику
AR109102A1 (es) Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert
UA115063U (xx) Спосіб лікування собак із больовим синдромом при панкреатиті
Erzin Fentanyl withdrawal
EA202090452A1 (ru) Соединения для лечения болезни фон гиппеля-линдау